RSS   Newsletter   Contact   Advertise with us

Zoetis sells plant and generics in India to Zydus Cadila

Share on Twitter Share on LinkedIn
Staff writer ▼ | January 6, 2016
Zoetis signed an agreement with the India-based pharmaceutical company Zydus Cadila for the divestment by Zoetis of a manufacturing site in Haridwar, India.
Haridwar
Pharma   A manufacturing site in Haridwar to be sold
The agreement also provides for the divestment by Zoetis of a portfolio of generic products which are associated with the Haridwar site. These products include medicated feed additives, anti-infectives, parasiticides, and nutritionals for livestock sold primarily in India.

Under the agreement, Zoetis will receive approximately $29 million in cash. The transaction is not material to Zoetis.

This transaction is an element of the Zoetis operational efficiency program announced on May 5, 2015, which is focused on reducing complexity, optimizing resource allocation and positioning the company for long-term profitable growth. The manufacturing site to be divested under the cgreement is among those Zoetis expects to sell or exit as part of the efficiency program.

The products to be divested under the Agreement represent a portion of the lower-revenue, relatively lower-margin product stock keeping units that Zoetis expects to eliminate to help improve profitability and enhance the reliability and efficiency of the Zoetis supply network.

Zoetis expects to complete the transaction in the first quarter of 2016.


 

MORE INSIDE POST